Medivizor

Title of notification

Here comes the notification
X
 
icon
prostate cancer | Research | 10 pages | source: JAMA network open | Added Sep 17, 2022

Evaluating the bone mineral density screening rates and their association with fracture rates among older men with prostate cancer receiving androgen deprivation therapy.

This study evaluated the bone mineral density (BMD) screening rates and their association with fracture rates among older men with prostate cancer (PC) receiving androgen deprivation therapy (ADT). The data showed that BMD screening is associated with a lower major fracture risk in these patients.

icon
prostate cancer | Research | 10 pages | source: The Oncologist | Added Sep 03, 2022

Evaluating the impact of immunetherapy on COVID-19 outcomes in patients with cancer.

This study evaluated the impact of immune checkpoint inhibitors (ICIs) on COVID-19 outcomes in patients with cancer. The data showed that the use of ICI treatment before COVID-19 infection does not affect the disease severity or survival outcomes. This study supports the continued use of ICIs in cancer patients during the pandemic.

icon
prostate cancer | Research | 10 pages | source: The Oncologist | Added Sep 01, 2022

Evaluating depression, anxiety, and patterns of mental health care in patients with prostate cancer receiving hormone therapy

This study evaluated depression, anxiety, and patterns of mental health care in patients with prostate cancer receiving hormonal therapy such as androgen deprivation therapy (ADT). The data showed that almost half of the patients with prostate cancer receiving ADT diagnosed with depression do not receive a documented mental health treatment.

icon
icon
prostate cancer | Research | Treatment | 10 pages | source: The Lancet. Oncology | Added Aug 14, 2022

Evaluating the benefits of adding androgen deprivation therapy to radiation therapy and extending its duration in men with localized prostate cancer.

This study evaluated the benefits of adding androgen deprivation therapy (ADT) to radiation therapy (RT) and the benefit of extending the duration of ADT in men with localized prostate cancer (PCa). The data showed that the addition of ADT to RT and extending the duration of ADT administered after RT significantly improved the survival without metastasis in men with localized PCa.

icon
prostate cancer | Research | 10 pages | source: The Lancet. Oncology | Added Aug 08, 2022

Evaluating the effects of olaparib on pain and the health-related quality of life in patients with metastatic castration-resistant prostate cancer.

This study evaluated the effects of olaparib (Lynparza) on pain and the health-related quality of life (HR-QoL) in patients with metastatic castration-resistant prostate cancer (mCRPC) with mutations (genetic abnormalities) in DNA repair genes. The data showed that treatment with olaparib was associated with a reduction in pain and improvement in HR-QoL compared with physician’s choice of hormone therapy in these patients.

icon
icon
prostate cancer | Research | Treatment | 10 pages | source: The New England Journal of Medicine | Added Jul 16, 2022

Evaluating the effectiveness and safety of darolutamide in combination with androgen deprivation therapy and docetaxel for metastatic hormone-sensitive prostate cancer.

This study evaluated the effectiveness and safety of darolutamide (Nubeqa) in combination with androgen deprivation therapy (ADT) and docetaxel (Taxotere) for the treatment of metastatic hormone-sensitive prostate cancer (mHSPC). The data showed that darolutamide in combination with ADT and docetaxel significantly improved the overall survival of these patients.

icon
icon
prostate cancer | Research | Treatment | 10 pages | source: Frontiers in oncology | Added Jun 14, 2022

Reviewing chemotherapy and hormonal therapy before prostate surgery in patients with prostate cancer

The review investigated the effects of neoadjuvant chemo-hormonal therapy (NCHT; chemotherapy and hormonal therapy before surgery) in patients with prostate cancer (PCa). The results showed that compared to patients who received prostate surgery alone, NCHT before prostate surgery improved the oncological outcomes of these patients.  

icon
icon
prostate cancer | Research | Treatment | 10 pages | source: PLOS ONE | Added Jun 05, 2022

Comparing Retzius-sparing and conventional robot-assisted radical prostatectomy for men with localized prostate cancer

This review compared the outcomes of 2 techniques for robotic-assisted radical prostatectomy (RARP; complete removal of the prostate gland using robotic arms): Retzius-sparing (RS)-RARP and conventional (C)-RARP in patients with localized prostate cancer (PCa). The analysis showed that RS-RARP was associated with improved urinary function compared to C-RARP, but with a higher risk of leaving cancer cells behind. 

icon
icon
prostate cancer | Research | Treatment | 10 pages | source: Lancet (London, England) | Added Jun 02, 2022

Evaluating the effectiveness and safety of adding abiraterone acetate and prednisolone with or without enzalutamide to androgen-deprivation therapy in patients with high-risk non-metastatic prostate cancer.

The study evaluated the effectiveness and safety outcomes of adding abiraterone acetate (AA; Zytiga) and prednisolone (P; Deltasone) with or without enzalutamide (Xtandi) to androgen-deprivation therapy (ADT) in patients with high-risk non-metastatic prostate cancer (PC). The data showed that AAP added to ADT significantly improved survival without metastasis compared to ADT alone in these patients.

icon
icon
prostate cancer | Research | Treatment | 10 pages | source: Frontiers in oncology | Added May 08, 2022

Comparing the effectiveness and safety of abiraterone acetate and enzalutamide for the treatment of metastatic castration-resistant prostate cancer.

This study compared the effectiveness and safety of abiraterone acetate (Zytiga; AA) and enzalutamide (Xtandi; ENZ) in patients with metastatic castration-resistant prostate cancer (mCRPC). The data showed that both medication improve outcomes compared to placebo and ENZ is more effective in improving survival without cancer progression and delaying PSA progression compared to AA for the treatment of patients with mCRPC.

View

Category

  • icon
  • icon
  • icon
  • icon
  • icon
  • icon
  • icon
  • icon
  • icon

Was this helpful?